Stockreport

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and si [Read more]